Your search returned 5 results.

Results
	1.	Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. MedStar authors: Brewer, H Bryan PMID: 27206939 Year: 2016 Citation: Journal of Clinical Lipidology. 10(3):519-527.e4, 2016 May-Jun Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Brewer HB, Deeg MA, Krueger KA, Liu L, Nicholls SJ, Nissen SE, Ruotolo G, Wang MD, Willey MB DOI: https://dx.doi.org/10.1016/j.jacl.2015.11.014 Add to cart (remove)
	2.	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. MedStar authors: Brewer, H Bryan PMID: 26564598 Year: 2015 Citation: Journal of the American College of Cardiology. 66(20):2201-10, 2015 Nov 17. Institution: MedStar Health Research Institute Medline publication type: Clinical Trial, Phase II Journal Article Multicenter Study Randomized Controlled Trial Form of publication: Journal Article All authors: Adelman SJ, Brewer HB, Kane JP, Krueger KA, Nicholls SJ, Nissen SE, Rader DJ, Ruotolo G, Wang MD DOI: http://dx.doi.org/10.1016/j.jacc.2015.09.013 Add to cart (remove)
	3.	New challenges for HDL-modifying therapies as a strategy to lower cardiovascular disease events in statin-treated patients. MedStar authors: Brewer, H Bryan Jr PMID: 25702643 Year: 2015 Citation: Cardiovascular Drugs & Therapy. 29(1):1-3, 2015 Feb. Institution: MedStar Heart & Vascular Institute Medline publication type: Comment Editorial Form of publication: Journal Article All authors: Brewer HB Jr, Rosenson RS DOI: http://dx.doi.org/10.1007/s10557-015-6576-7 Add to cart (remove)
	4.	Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome. [Review] MedStar authors: Brewer, H Bryan PMID: 24902972 Year: 2014 Citation: Circulation Research. 114(12):1880-9, 2014 Jun 6. Institution: MedStar Health Research Institute Medline publication type: Journal Article Review Form of publication: Journal Article All authors: Brewer HB, Rader DJ, Rosenson RS DOI: http://dx.doi.org/10.1161/CIRCRESAHA.114.302805 Add to cart (remove)
	5.	Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. MedStar authors: Brewer, H Bryan PMID: 26047975 Year: 2015 Citation: Lancet. 386(9992):452-60, 2015 Aug 1. Institution: MedStar Health Research Institute Medline publication type: Clinical Trial, Phase II Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Barter PJ, Brewer HB, Ford J, Hovingh GK, Kastelein JJ, Rader DJ, Round P, Saleheen D, van Deventer SJ DOI: http://dx.doi.org/10.1016/S0140-6736(15)60158-1 Add to cart (remove)

Powered by Koha